Next-generation sequencing of pancreatic juice can detect and quantify tumor-promoting mutations, supporting imaging and cytology findings to predict the degree of dysplasia in patients at high risk for pancreatic cancer. Future studies are needed to optimize this approach and determine how it best fits into clinical practice. Clin Cancer Res; 24(12); 2713–5. ©2018 AACR.
See related article by Suenaga et al., p. 2963
https://ift.tt/2sXbNEr
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου